Stryker Corporation $SYK Shares Bought by Diversified Trust Co.

Diversified Trust Co. raised its position in Stryker Corporation (NYSE:SYKFree Report) by 58.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,704 shares of the medical technology company’s stock after buying an additional 7,259 shares during the period. Diversified Trust Co.’s holdings in Stryker were worth $6,925,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of SYK. Clayton Financial Group LLC acquired a new stake in shares of Stryker during the 3rd quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the 3rd quarter worth about $27,000. Elevation Point Wealth Partners LLC purchased a new position in Stryker during the second quarter worth approximately $28,000. Kilter Group LLC purchased a new position in Stryker during the second quarter worth approximately $29,000. Finally, Howard Hughes Medical Institute acquired a new stake in Stryker in the second quarter valued at approximately $29,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 1.0%

Shares of SYK opened at $332.48 on Tuesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker Corporation has a one year low of $328.23 and a one year high of $404.87. The stock has a market capitalization of $127.24 billion, a price-to-earnings ratio of 39.58, a PEG ratio of 1.96 and a beta of 0.85. The stock has a 50 day moving average price of $362.68 and a 200 day moving average price of $365.29.

Stryker (NYSE:SYKGet Free Report) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. During the same quarter last year, the firm posted $4.01 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 41.90%.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

Analyst Ratings Changes

Several brokerages have recently weighed in on SYK. Jefferies Financial Group reaffirmed a “buy” rating and set a $465.00 target price on shares of Stryker in a research note on Wednesday, March 4th. BTIG Research lifted their price target on shares of Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Citigroup restated a “market outperform” rating on shares of Stryker in a research report on Friday, January 30th. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective on the stock in a report on Tuesday, January 6th. Finally, UBS Group dropped their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Fourteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average target price of $427.50.

Read Our Latest Analysis on SYK

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.20% of the company’s stock.

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Articles

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.